AbbVie has received FDA approval for Vyalev, a novel combination therapy for advanced Parkinson’s disease that delivers carbidopa and levodopa via a 24-hour infusion, addressing challenges with oral medications. This approval follows two previous rejections and is based on positive results from late-stage clinical trials. Patient access will vary by insurance, with Medicare coverage anticipated in late 2025, and AbbVie projects peak annual sales could exceed $1 billion.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
